AGRN and proximal spinal muscular atrophy: Interventions to stabilize the NMJ in mouse models of ALS and SMA (such as activation of MuSK using agonist antibodies and increasing agrin function using a synthetic agrin fragments) do not rescue the neuromuscular pathology but provide modest delays in NMJ decline [148,149].